rhealth

rhealth

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.5M

Overview

Founded in 2015 by Dr. Eugene Chan, rHEALTH is a pioneering diagnostics company commercializing portable, single-drop blood analyzers originally developed for NASA to monitor astronaut health in space. The company has a strong technical foundation, validated by successful on-orbit testing, numerous patents, and prestigious awards like the Qualcomm Tricorder XPRIZE. rHEALTH aims to transform point-of-care and remote diagnostics by providing lab-quality results autonomously and immediately, targeting both terrestrial healthcare and future space missions.

Diagnostics

Technology Platform

Portable, single-drop blood analyzer using nanostrips, microfluidics, and laser detection for multiplexed, autonomous diagnostic testing. Derived from NASA spaceflight requirements.

Funding History

2
Total raised:$10.5M
Series A$8M
Seed$2.5M

Opportunities

The global shift towards decentralized, point-of-care testing creates a massive market for a portable, comprehensive diagnostic device.
The company's first-mover advantage in spaceflight diagnostics with NASA provides a unique, validated niche and a pathway to supply future long-duration missions.

Risk Factors

The primary risk is navigating the complex and costly FDA regulatory pathway to transition from investigational to approved clinical use.
Additional risks include scaling manufacturing, achieving cost targets, and competing against established diagnostic companies in a crowded market.

Competitive Landscape

rHEALTH competes in the broad point-of-care diagnostics market against giants like Abbott (i-STAT), Roche, and Siemens, as well as newer entrants in lab-on-a-chip and wearable sensing. Its key differentiators are the breadth of tests from a single drop, full automation, and its unique validation for extreme environments via NASA.